MDM2 as MYCN transcriptional target: Implications for neuroblastoma pathogenesis

Cancer Letters

Volumn 228, Issue 1-2, 2005, Pages 21-27

  Slack, Andrew ^a   Lozano, Guillermina ^b   Shohet, Jason M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; MDM2; MYCN; Neuroblastoma; p53

Indexed keywords

ETOPOSIDE; MYC PROTEIN; MYCN PROTEIN; N MYC ONCOGENE PROTEIN; ONCOPROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER DIAGNOSIS; CANCER RISK; CARCINOGENESIS; CELL LINE; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE INACTIVATION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HIGH RISK PATIENT; HUMAN; LYMPHOMA; MULTIDRUG RESISTANCE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SHORT SURVEY; TARGET CELL DESTRUCTION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

EID: 23944445607     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.01.050     Document Type: Review

References (64)

1. M. Schwab MYCN in neuronal tumours Cancer Lett. 204 2004 179 187
2. W.A. Weiss, K. Aldape, G. Mohapatra, G.B.G. Feuerstein, and J.M. Bishop Targeted expression of MYCN causes neuroblastoma in transgenic mice Embo J. 16 1997 2985 2995
3. C.E. Nesbit, J.M. Tersak, and E.V. Prochownik MYC oncogenes human neoplastic disease Oncogene 18 1999 3004 3016
4. D.W. Felsher, and J.M. Bishop Transient excess of MYC activity can elicit genomic instability and tumorigenesis Proc. Natl. Acad. Sci. USA 96 1999 3940 3944
5. W. Lutz, M. Stohr, J. Schurmann, A. Wenzel, A. Lohr, and M. Schwab Conditional expression of N-myc in human neuroblastoma cells increases expression of alpha-prothymosin and ornithine decarboxylase and accelerates progression into S-phase early after mitogenic stimulation of quiescent cells Oncogene 13 1996 803 812
6. T. Fotsis, S. Breit, W. Lutz, J. Rossler, E. Hatzi, M. Schwab, and L. Schwiegerer Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells Eur. J. Biochem. 263 1999 757 764
7. L. Schweigerer, S. Breit, A. Wenzel, K. Tsunamoto, R. Ludwig, and M. Schwab Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity Cancer Res. 50 1990 4411 4416
8. M.M. van Noesel, and R. Versteeg Pediatric neuroblastomas: genetic and epigenetic danse macabre Gene 325 2004 1 15
9. J.A. Nilsson, and J.L. Cleveland Myc pathways provoking cell suicide and cancer Oncogene 22 2003 9007 9021
10. M.D. Hogarty The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification Cancer Lett. 197 2003 173 179
11. A.S. Weinmann, and P.J. Farnham Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation Methods 26 2002 37 47
12. A. Slack, Z. Chen, R. Tonelli, M. Pule, L. Hunt, A. Pession, and J.M. Shohet The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma Proc. Natl. Acad. Sci. USA 102 3 2005 731 736
13. G. Hosoi, J. Hara, T. Okamura, S. Osugi, M. Ishihara, and A. Fukuzawa Low frequency of the p53 gene mutations in neuroblastoma Cancer 73 1994 3087 3093
14. K. Vogan, M. Bernstein, J.M. Leclerc, L. Brisson, J. Brossard, and G.M. Brodeur Absence of p53 gene mutations in primary neuroblastomas Cancer Res. 53 1993 5269 5273
15. S.S. Fakharzadeh, S.P. Trusko, and D.L. George Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line Embo J. 10 1991 1565 1569
16. C.A. Finlay The mdm-2 oncogene can overcome wild-type p53 suppression of transformed cell growth Mol. Cell Biol. 13 1993 301 306
17. G. Ganguli, and B. Wasylyk p53-independent functions of MDM2 Mol. Cancer Res. 1 2003 1027 1035
18. G. Reifenberger, L. Liu, K. Ichimura, E.E. Schmidt, and V.P. Collins Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations Cancer Res. 53 1993 2736 2739
19. F.S. Leach, T. Tokino, P. Meltzer, M. Burrell, J.D. Oliner, and S. Smith p53 mutation and MDM2 amplification in human soft tissue sarcomas Cancer Res. 53 1993 2231 2234
20. C. Cordon-Cardo, E. Latres, M.r. Drobnjak, D. Oliva, and J.M. Pollack Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas Cancer Res. 54 1994 794 799
21. P. Wurl, A. Meye, H. Schmidt, C. Lautenschlager, H. Kalthoff, F.W. Rath, and H. Taubert High prognostic significance of Mdm2/p53 co-overexpression in soft tissue sarcomas of the extremities Oncogene 16 1998 1183 1185
22. M.B. Moller, O. Nielsen, and N.T. Pedersen Oncoprotein MDM2 overexpression is associated with poor prognosis in distinct non-Hodgkin's lymphoma entities Mod. Pathol. 12 1999 1010 1016
23. K.B. Pagnano, J. Vassallo, I. Lorand-Metze, F.F. Cosat, and S.T. Saad p53, Mdm2, and c-Myc overexpression is associated with a poor prognosis in aggressive non-Hodgkin's lymphomas Am. J. Hematol. 67 2001 84 92
24. M.C. Finnegan, J.R. Goepel, J. Royds, B.W. Hancock, and M.H. Goyns Elevated levels of MDM-2 and p53 expression are associated with high grade non-Hodgkin's lymphomas Cancer Lett. 86 1994 215 221
25. M. Oren Decision making by p53: life, death and cancer Cell Death Differ. 10 2003 431 442
26. S.P. Deb Cell cycle regulatory functions of the human oncoprotein MDM2 Mol. Cancer Res. 1 2003 1009 1016
27. J. Momand, G.P. Zambetti, D.C. Olson, D. George, and A.J. Levine The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell 69 1992 1237 1245
28. J. Roth, M. Dobbelstein, D.A. Freedman, T. Shenk, and A.J. Levine Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein Embo J. 17 1998 554 564
29. D.A. Freedman, and A.J. Levine Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6 Mol. Cell Biol. 18 1998 7288 7293
30. M.H. Kubbutat, S.N. Jones, and K.H. Vousden Regulation of p53 stability by Mdm2 Nature 387 1997 299 303
31. R. Honda, H. Tanaka, and H. Yasuda Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53 Fed. Eur. Biochem. Soc. Lett. 420 1997 25 27
32. Y. Haupt, R. Maya, A. Kazaz, and M. Oren Mdm2 promotes the rapid degradation of p53 Nature 387 1997 296 299
33. Y. Jin, H. Lee, S.X. Zeng, M.S. Dai, and H. Lu MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation Eur. Mol. Biol. Org J. 22 2003 6365 6377
34. K. Martin, D. Trouche, C. Hagemeier, T.S. Sorensen, N.B. LaThangue, and T. Kouzarides Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein Nature 375 1995 691 694
35. Z.X. Xiao, J. Chen, A.J. Levine, N. Modjtahedi, J. Xing, W.R. Sellers, and D.M. Livingston Interaction between the retinoblastoma protein and the oncoprotein MDM2 Nature 375 1995 694 698
36. E. Kobet, X. Zeng, Y. Zhu, D. Keller, and H. Lu MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins Proc. Natl. Acad. Sci. U.S.A. 97 2000 12547 12552
37. K. Lundgren, R. Montes de Oca Luna, Y.B. McNeill, E.P. Emerick, B. Spencer, and C.R. Barfield Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53 Genes Dev. 11 1997 714 725
38. H. Komuro, Y. Hayashi, M. Kawamura, K. Hayashi, Y. Kaneko, and S. Kamoshita Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas Cancer Res. 53 1993 5284 5288
39. S.C. Goldman, C.Y. Chen, T.J. Lansing, T.M. Gilmer, and M.B. Kastan The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization Am. J. Pathol. 148 1996 1381 1385
40. D.A. Tweddle, A.J. Malcolm, M. Cole, A.D. Pearson, and J. Lunec p53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells Am. J. Pathol. 158 2001 2067 2077
41. P.P. McKenzie, S.M. Guichard, D.S. Middlemas, R.A. Ashmun, M.K. Danks, and L.C. Harris Wild-type p53 can induce p21 and apoptosis in neuroblastoma cells but the DNA damage-induced G1 checkpoint function is attenuated Clin. Cancer Res. 5 1999 4199 4207
42. A.M. Rodriguez-Lopez, D. Xenaki, T.O. Eden, J.A. Hickman, and C.M. Chresta MDM2 mediated nuclear exclusion of p53 attenuates etoposide-induced apoptosis in neuroblastoma cells Mol. Pharmacol. 59 2001 135 143
43. N. Keshelava, J.J. Zuo, P. Chen, S.N. Waidyaratne, M.C. Luna, and C.J. Gomer Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines Cancer Res. 61 2001 6185 6193
44. J.S. Isaacs, S. Saito, and L.M. Neckers Requirement for HDM2 activity in the rapid degradation of p53 in neuroblastoma J. Biol. Chem. 276 2001 18497 18506
45. S.N. Jones, A.E. Roe, L.A. Donehower, and A. Bradley Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53 Nature 378 1995 206 208
46. R. Montes de Oca Luna, D.S. Wagner, and G. Lozano Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53 Nature 378 1995 203 206
47. A. Chavez-Reyes, J.M. Parant, L.L. Amelse, R. Montes de Oca Luna, S.J. Korsmeyer, and G. Lozano Switching mechanisms of cell death in mdm2- and mdm4-null mice by deletion of p53 downstream targets Cancer Res. 63 2003 8664 8669
48. T.J. McDonnell, R. Montes de Oca Luna, S. Cho, L.L. Amelse, A. Chavez-Reyes, and G. Lozano Loss of one but not two mdm2 null alleles alters the tumour spectrum in p53 null mice J. Pathol. 188 1999 322 328
49. J.M. Adams, A.W. Harris, C.A. Pinkert, L.M. Corcoran, W.S. Alexander, and S. Cory The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice Nature 318 1985 533 538
50. J.R. Alt, T.C. Greiner, J.L. Cleveland, and C.M. Eischen Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis Eur. Mol. Biol. Org J. 22 2003 1442 1450
51. G.L. Bond, W. Hu, E.E. Bond, H. Robins, S.G. Lutzker, and N.C. Arva A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans Cell 119 2004 591 602
52. W. Lutz, S. Fulda, I. Jeremias, K.M. Debatin, and M. Schwab MYCN and IFNgamma cooperate in apoptosis of human neuroblastoma cells Oncogene 17 1998 339 346
53. T. Teitz, T. Wei, M.B. Valentine, E.F. Vanin, J. Grenet, and V.A. Valentine Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN Nat. Med. 6 2000 529 535
54. J. Takita, H.W. Yang, F. Bessho, R. Hanada, K. Yamamoto, and V. Kidd Absent or reduced expression of the caspase 8 gene occurs frequently in neuroblastoma, but not commonly in Ewing sarcoma or rhabdomyosarcoma Med. Pediatr. Oncol. 35 2000 541 543
55. V.P. Castle, K.P. Heidelberger, J. Bromberg, X. Ou, M. Dole, and G. Nunez Expression of the apoptosis-suppressing protein bcl-2, in neuroblastoma is associated with unfavorable histology and N-myc amplification, Am J. Pathol. 143 1993 1543 1550
56. C. Adida, D. Berrebi, M. Peuchmaur, M. Reyes-Mugica, and D.C. Altieri Anti-apoptosis gene, surviving, and prognosis of neuroblastoma Lancet 351 1998 882 883
57. S.J. Korsmeyer Bcl-2 initiates a new category of oncogenes: regulators of cell death Blood 80 1992 879 886
58. F. Zindy, C.M. Eischen, D.H. Randle, T. Kamijo, J.L. Cleveland, C.J. Sherr, and M.F. Roussel Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization Genes Dev. 12 1998 2424 2433
59. T. Kamijo, F. Zindy, M.F. Roussel, D.E. Quelle, J.R. Downing, and R.A. Ashmun Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF Cell 91 1997 649 659
60. J. Pomerantz, N. Schreiber-Agus, N.J. Liegeois, A. Silverman, L. Alland, and L. Chin The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53 Cell 92 1998 713 723
61. L.M. Hansford, W.D. Thomas, J.M. Keating, C.A. Burkhart, A.E. Peaston, and M.D. Norris Mechanisms of embryonal tumor initiation: distinct roles for MYCN expression and MYCN amplification Proc. Natl. Acad. Sci. USA 101 2004 12664 12669
62. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, and Z. Filipovic In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
63. Z. Zhang, M. Li, H. Wang, S. Agrawal, and R. Zhang Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy Proc. Natl. Acad. Sci. USA 100 2003 11636 11641
64. Z. Zhang, H. Wang, G. Prasad, M. Li, D. Yu, and J.A. Bonner Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models Clin. Cancer Res. 10 2004 1263 1273